Medical Device

BioTelemetry (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter ended December 31, 2017. As quoted in the press release: “As we enter 2018, we are very well-positioned for continued success.  …

BioTelemetry (NASDAQ:BEAT), the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter ended December 31, 2017.

As quoted in the press release:

“As we enter 2018, we are very well-positioned for continued success.  We have the largest and most productive sales force in the industry, selling the most comprehensive suite of cardiac monitoring solutions with more products being introduced in 2018.  We are experiencing accelerated growth in our Research business, with double digit growth expected for the year.  Additionally, we have established strategic relationships in our digital population health business, which have the potential to drive significant future growth.  Given these factors, we have an abundance of opportunities on which to capitalize, and we expect 2018 to be another standout year for the Company, with approximately $380 million of revenue and an adjusted EBITDA margin percent in the mid-twenties.”

Click here to read the full press release.

MARKETS

Markets
TSX19065.26+203.90
TSXV621.75+4.49
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6539.90-28.20

COMMODITIES

Commodities
Gold1807.22-1.19
Silver19.93+0.07
Copper3.57-0.14
Palladium1941.50-3.50
Platinum887.00+1.00
Oil110.57+4.81
Heating Oil3.95+0.12
Natural Gas5.84+0.23

DOWNLOAD FREE REPORTS

×